Annual awards program recognizes innovations and achievements in global biopharma Wellesley, Mass., September 28, 2022 – Qlaris Bio, Inc, a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today it has been named a finalist in the WuXi AppTec’s Biotech Company of the Year category of the 2022 Scrip Awards. Qlaris has seen […]
News
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101 Findings from First-in-Human Study Support Continued Clinical Development of Investigational IOP-lowering Therapy; New Trials Planned as Complementary Glaucoma Treatment and in Rare Pediatric Indication Wellesley, Mass., May 18, 2022 – Qlaris Bio, Inc. (the “Company” or “Qlaris”), […]
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational TherapyDesigned to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma -Phase 1/2 Initiation Follows FDA Acceptance of Investigational New Drug (IND) Application- Wellesley, Mass., April 15, 2021 — Qlaris Bio, Inc., a biotechnology company targeting high unmet needs in debilitating ophthalmic […]